Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: A systematic review and meta-analysis

Clinical Drug Investigation

Volumn 33, Issue 5, 2013, Pages 325-331

  Bota, Simona ^a   Sporea, Ioan ^a   Şirli, Roxana ^a   Neghină, Adriana Maria ^a   Popescu, Alina ^a   Străin, Mihnea ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; TELAPREVIR;

ALLELE; ANTIVIRAL THERAPY; CHEMOTHERAPY; GENOTYPE; HEPATITIS C; HUMAN; META ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 84877049762     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0074-0     Document Type: Review

References (40)

1. WHO. Global surveillance and control of Hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Liver. 1999;6(1):34-5.
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-65.
3. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346-55.
4. Sporea I, Sirli R, Curescu M, et al. Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis: a retrospective study in 507 patients. J Gastrointestin Liver Dis. 2010;19(3):261-4.
5. Marcellin P, Cheinquer H, Curescu M, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology. 2012;56(6):2039-50.
6. Bota S, Sporea I, Popescu A, et al. Response to standard of care antiviral treatment in patients with HCV liver cirrhosis: a systematic review. J Gastrointestin Liver Dis. 2011;20(3):293-8.
7. Syed E, Rahbin N, Weiland O, et al. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh A liver cirrhosis. Scand J Gastroenterol. 2008;43(11):1378-86.
8. Fernandez-Rodriguez C, Alonso S, Martinez SM, et al. PegInterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol. 2010;105(10):2164-72.
9. Rauch A, Kutalik Z, Descombes P, et al. Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138(4):1338-45.
10. Grebely J, Petoumenos K, Hellard M, et al. ATAHC Study Group. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology. 2010;52(4):1216-24.
11. Li S, Hu P, Zhang QQ, et al. Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-Interferon/ ribavirin therapy: a meta-analysis. Hepat Mon. 2011;11(3):163-72.
12. Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin. Aliment Pharmacol Ther. 2012;36(2):91-103.
13. Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol. 2011;8(5):257-64.
14. McHutchison JG, Manns MP, Muir AJ, et al. PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010; 362(14):1292-330.
15. Smith LS, Nelson M, Naik S, Woten J. Telaprevir: an NS3/4A Protease inhibitor for the treatment of chronic hepatitis C. Ann Pharmacother. 2011;45(5):639-48.
16. Poordad F, McCone J Jr, Bacon BR, et al. SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-206.
17. Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology. 2011;140(2):459-68.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88.
19. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-34.
20. Chayama K, Nelson Hayes C, Abe H. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis. 2011;204(1):84-93.
21. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, et al. Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. Intervirology. 2012;55(3):231-41.
22. Suzuki F, Suzuki Y, Akuta N, et al. Influence of ITPA polymorphisms on decrease of hemoglobin during treatment with pegylated interferon, ribavirin and telaprevir. Hepatology. 2011;53(2):415-21.
23. Poordad F, Bronowicki JP, Gordon SC, et al. SPRINT-2 and RESPOND-2 Investigators. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology. 2012;143(3):608-18.
24. Pol S, Aerssens J, Zeuzem S, et al. Similar SVR rates in IL28B CC, CT or TT prior relapser, partial or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the REALIZE study [abstract]. J Hepatol. 2011;54(Suppl 1):S6.
25. Jacobson IM, Catlett I, Marcellin P, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial [abstract]. J Hepatol. 2011;54(Suppl 1):S542.
26. Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the Interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010;52(2):421-9.
27. Bronowicki JP, Hezode C, Bengtsson L, et al. 100% SVR in IL28B CC patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the PROVE2 trial [abstract]. J Hepatol. 2012;56(Suppl 2):S430.
28. Bacon BR, Gordon SC, Lawitz E, et al. HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207-17.
29. Zeuzem S, Andreone P, Pol S; REALIZE Study Team, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417-28.
30. Jacobson IM, McHutchison JG, Dusheiko G, et al. ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-16.
31. Hézode C, Forestier N, Dusheiko G, et al. PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360(18):1839-50.
32. Mauss S, Hueppe D, John C, et al. Estimating the likelihood of sustained virological response in chronic hepatitis C therapy. J Viral Hepat. 2011;18(4):e81-90.
33. Reddy KR, Govindarajan S, Marcellin P, et al. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hep. 2008;15(2):129-36.
34. Yamada G, Iino S, Okuno T, et al. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Clin Drug Investig. 2008;28(1):9-16.
35. Fried MW, Hadziyannis SJ, Shiffman ML, et al. Rapid virological response is the most important predictor of virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol. 2011;55(1):69-75.
36. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399-401.
37. Sporea I, Popescu A, Curescu M, et al. The correlation of Il28B genotype with sustained virologic response in Romanian patients with chronic hepatitis C. Hepat Mon. 2011;11(12):975-9.
38. McHutchison JG. The role of genetic markers in hepatitis C virus therapy: a major step to individualized care. Liver Int. 2011;31(Suppl 1):29-35.
39. Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology. 2005;128(5):1437-44.
40. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A. 2008;105(19):7034-9.